Telix Pharmaceuticals (TLPPF) Other Non-Current Liabilities (2023 - 2026)

Telix Pharmaceuticals (TLPPF) has reported Other Non-Current Liabilities for 4 consecutive years, with $3.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Non-Current Liabilities changed N/A year-over-year to $3.2 million in Q2 2026; TTM through Jun 2026 was $3.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at $3.5 million, down 93.39% from the prior year.
• Other Non-Current Liabilities was $3.2 million for Q2 2026 at Telix Pharmaceuticals, down from $3.5 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $56.2 million in Q4 2024 and troughed at $3.2 million in Q2 2026.
• A 4-year average of $21.8 million and a median of $13.9 million in 2023 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities surged 132.29% in 2024 and slumped 93.74% in 2025, its largest moves.
• Over 4 years, Other Non-Current Liabilities stood at $24.2 million in 2023, then surged by 132.29% to $56.2 million in 2024, then tumbled by 93.74% to $3.5 million in 2025, then declined by 8.33% to $3.2 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $3.2 million (Q2 2026), $3.5 million (Q4 2025), and $56.2 million (Q4 2024), per Business Quant data.